It is also of interest to note that postmenopausal breast cancer patients on neoadjuvant aromatase therapy were found to have elevated STS and 17β-HSD type-1 expression in their tumours, indicating a potential compensatory response of breast carcinoma tissue to oestrogen depletion. Here, CYP19A1 is linked to breast cancer.